The primary affected person has been enrolled within the ARID II trial for prostate most cancers: inventory.adobe.com.
The primary affected person has been enrolled within the pivotal ARID II trial, which is designed to analyze the security and effectiveness of Voro Urologic Scaffold in grownup males with prostate most cancers present process robotic assisted radical prostatectomy, as in contrast with management, in accordance with a information launch from Leevee Medical.
The Voro Urologic Scaffold is designed to ease stress on the urinary sphincter by extending the efficient urethra after robot-assisted radical prostatectomy, in accordance with a examine printed in Urologia Internationalis. It’s positioned on the anastomotic web site, protecting the bladder neck and urethral stump after the prostate is eliminated and earlier than the anastomosis is created.
Mississippi Baptist Medical Heart was the primary web site to enroll a affected person onto the ARID II examine, led by Dr. Patrick Each day.
“What is really thrilling is the potential for this machine to meaningfully enhance early and long-term continence charges, which may profoundly impression a affected person’s restoration and total high quality of life,” stated Each day within the information launch. “We’re excited to be the primary web site to enroll within the examine and I look ahead to seeing the outcomes as soon as the examine is full.”
Each day is a board-certified urologic surgeon at Mississippi Urology Clinic. He’s additionally a member of the American Urological Affiliation, Endourological Society, Mississippi State Medical Affiliation and Central Mississippi Medical Society.
“Initiating the ARID II trial marks an necessary step as we construct upon the promising outcomes of our preliminary feasibility examine,” Bruce Choi, founder, director, CTO and chairman of Levee Medical, stated within the information launch. “This subsequent section brings us nearer to offering a brand new normal of look after males recovering from prostate most cancers surgical procedure.”
The ARID II examine has launched following constructive outcomes from the section 2 ARID feasibility examine, which enrolled 28 sufferers, the corporate introduced in a earlier information launch.
“Our expertise with the Voro Urologic Scaffold has been extraordinarily encouraging,” stated principal investigator Dr. Gustavo Espino of Hospital Nacional in Panama Metropolis within the information launch. “The machine had an impressive security profile, and sufferers have famous early enhancements in continence, which interprets to a significantly higher high quality of life post-surgery.”
The potential feasibility examine goals to enroll 40 grownup sufferers throughout three medical trial websites in Panama. Eligible members have to be 45 to 70 years previous, have Gleason grade group 3 or decrease prostate most cancers, and a prostate measurement below 80 grams.
The trial’s main endpoint is change in pad weight on a 24-hour pad weight take a look at from baseline to six and 12 months after radical prostatectomy. Secondary measures embrace change within the standing cough take a look at over a particular interval.
Examine completion is anticipated in October 2026.
The machine can also be being evaluated within the observational ALTO examine, which started enrolling sufferers in June 2024. That examine is monitoring urinary operate and high quality of life in sufferers post-radical prostatectomy, with completion anticipated in March 2026.
Prostate most cancers varieties within the prostate, a gland under the bladder within the male reproductive system, and often impacts older males, in accordance with the Nationwide Most cancers Institute. Remedy might contain a prostatectomy, the surgical elimination of half or the entire prostate, close by tissue and generally lymph nodes. This may be achieved via open surgical procedure, laparoscopy or robotic help, with care taken to guard nerves that management bladder operate and erections at any time when attainable.
Reference:
“Preliminary Expertise with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of two Instances,” by Dr. Michael N. Ferrandino, et al., Urologia Internationalis.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
